RU96122469A - Матричные гранулы продленного действия и способ их получения - Google Patents

Матричные гранулы продленного действия и способ их получения

Info

Publication number
RU96122469A
RU96122469A RU96122469/14A RU96122469A RU96122469A RU 96122469 A RU96122469 A RU 96122469A RU 96122469/14 A RU96122469/14 A RU 96122469/14A RU 96122469 A RU96122469 A RU 96122469A RU 96122469 A RU96122469 A RU 96122469A
Authority
RU
Russia
Prior art keywords
matrix granules
prolonged action
paragraphs
extrusion
carried out
Prior art date
Application number
RU96122469/14A
Other languages
English (en)
Other versions
RU2155031C2 (ru
Inventor
Грабовски Свен
Розенберг Ерг
Заннер Аксель
Original Assignee
Басф Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4413350A external-priority patent/DE4413350A1/de
Application filed by Басф Аг filed Critical Басф Аг
Publication of RU96122469A publication Critical patent/RU96122469A/ru
Application granted granted Critical
Publication of RU2155031C2 publication Critical patent/RU2155031C2/ru

Links

Claims (8)

1. Матричные гранулы продленного действия шарико- или чечевицеобразной формы с единым максимальным диаметром, составляющим 0,5 - 4 мм, состоящие из
а) 0,1 - 87 вес.% по меньшей мере одного биологически активного соединения;
б) 5 - 50 вес.% по меньшей мере одного водонерастворимого полимера;
в) 5 - 45 вес.% по меньшей мере одного липофильного компонента в качестве пластификатора полимера б);
г) 3 - 40 вес.% природного или полусинтетического гелеобразователя,
д) 0 - 50 вес.% одного или нескольких стандартных вспомогательных веществ.
2. Матричные гранулы продленного действия по п. 1, отличающиеся следующими концентрациями компонентов:
а) 1 - 75 вес.%,
б) 10 - 40 вес.%,
в) 10 - 35 вес.%,
г) 5 - 25 вес.%,
д) 0 - 40 вес.%.
3. Матричные гранулы продленного действия по п. 1 или 2, отличающиеся тем, что максимальный диаметр составляет 0,8 - 2 мм.
4. Матричные гранулы продленного действия по одному из пп. 1 - 3, отличающиеся тем, что активное начало (а) по своей природе является фармацевтическим.
5. Непрерывный, одностадийный способ получения матричных гранул продленного действия по одному из пп. 1 - 4 путем экструзии расплавленной смеси компонентов при 50 - 200°С и непрерывного формования.
6. Способ по п. 5, отличающийся тем, что экструзию проводят при 50 - 180°С.
7. Способ по п. 5, отличающийся тем, что экструзию проводят при 60 - 150°С.
8. Способ по одному из пп. 5 - 7, отличающийся тем, что формование осуществляют путем обрезания в горячем состоянии.
RU96122469/14A 1994-04-18 1995-04-05 Матричные гранулы продленного действия RU2155031C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4413350A DE4413350A1 (de) 1994-04-18 1994-04-18 Retard-Matrixpellets und Verfahren zu ihrer Herstellung
DEP4413350.2 1994-04-18

Publications (2)

Publication Number Publication Date
RU96122469A true RU96122469A (ru) 1999-01-20
RU2155031C2 RU2155031C2 (ru) 2000-08-27

Family

ID=6515707

Family Applications (1)

Application Number Title Priority Date Filing Date
RU96122469/14A RU2155031C2 (ru) 1994-04-18 1995-04-05 Матричные гранулы продленного действия

Country Status (23)

Country Link
US (1) US6290990B1 (ru)
EP (1) EP0756480B1 (ru)
JP (1) JP4099225B2 (ru)
KR (1) KR100371885B1 (ru)
CN (1) CN1131024C (ru)
AT (1) ATE204747T1 (ru)
AU (1) AU2256495A (ru)
BR (1) BR9507328A (ru)
CA (1) CA2188185C (ru)
CZ (1) CZ301396A3 (ru)
DE (2) DE4413350A1 (ru)
DK (1) DK0756480T3 (ru)
ES (1) ES2162635T3 (ru)
FI (1) FI964175A (ru)
HU (1) HU221981B1 (ru)
IL (1) IL113316A (ru)
MX (1) MXPA96004911A (ru)
NO (1) NO313735B1 (ru)
NZ (1) NZ284064A (ru)
PL (1) PL317936A1 (ru)
PT (1) PT756480E (ru)
RU (1) RU2155031C2 (ru)
WO (1) WO1995028147A1 (ru)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE19531277A1 (de) * 1995-08-25 1997-02-27 Basf Ag Verwendung von Lipiden als Hilfsmittel bei der Herstellung von festen Arzneiformen nach dem Schmelzextrusionsverfahren
DE19539362A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
DE19539360A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
FR2748209B1 (fr) * 1996-05-06 1998-06-05 Adir Composition pharmaceutique a base de matrices lipophiles stabilisees pour la liberation controlee de principes actifs
DE19637082A1 (de) 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
US8828432B2 (en) * 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
FR2761605B1 (fr) * 1997-04-07 2001-02-23 Prographarm Lab Forme pharmaceutique multiparticulaire, ses particules constitutives, procede et installation pour leur fabrication
AU747549B2 (en) * 1998-03-23 2002-05-16 General Mills Inc. Encapsulation of components into edible products
DE19842753A1 (de) 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
BR0012869A (pt) 1999-07-30 2002-05-21 Smithkline Beecham Plc Forma de dosagem farmacêutica de componentes múltiplos
DE10045904B4 (de) * 1999-10-01 2007-07-12 Degussa Gmbh alpha-Liponsäure(-Derivate) enthaltende Retardform
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
JP5767429B2 (ja) * 1999-11-12 2015-08-19 アッヴィ・インコーポレイテッド 固体分散剤中の結晶化阻害剤
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
AU5066101A (en) * 2000-04-13 2001-10-30 Synthon B.V. Modified release formulations containing a hypnotic agent
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
EP2263658A1 (en) 2000-10-30 2010-12-22 Euro-Celtique S.A. Controlled release hydrocodone formulations
US7883721B2 (en) 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US7842308B2 (en) * 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US20030198671A1 (en) * 2001-08-10 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique plasma AUC properties
DE10150938A1 (de) * 2001-10-04 2003-04-24 Frunol Delicia Gmbh Schädlingsbekämpfungsmittel und Verfahren zu dessen Herstellung
US20030180356A1 (en) * 2001-10-29 2003-09-25 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
US7700134B2 (en) * 2002-01-17 2010-04-20 The Regents Of The University Of Michigan Prevention of cisplatin induced deafness
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
US20050182056A9 (en) * 2002-02-21 2005-08-18 Seth Pawan Modified release formulations of at least one form of tramadol
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
BR0312206A (pt) * 2002-06-27 2005-04-12 Cilag Ag Formulações de pélete esférico
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
CA2491572C (en) * 2002-07-05 2010-03-23 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US8840928B2 (en) 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
WO2004014318A2 (en) * 2002-08-10 2004-02-19 King Pharmaceuticals, Inc. Levothyroxine compositions and methods
DE10247037A1 (de) * 2002-10-09 2004-04-22 Abbott Gmbh & Co. Kg Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers
KR20040043589A (ko) * 2002-11-19 2004-05-24 경동제약 주식회사 서방성 세파클러 제제 및 그 제조방법
SI21353A (sl) * 2002-11-27 2004-06-30 Lek farmacevtska družba, d.d. Pelete vsebujoče brezvodne tekočine in proces njihove priprave
ES2208123A1 (es) * 2002-11-29 2004-06-01 Laboratorios Del Dr. Esteve, S.A. Uso de los compuestos 2,5-dihidroxibencenosulfonicos para la fabricacion de un medicamento.
ES2208124B1 (es) * 2002-11-29 2005-10-01 Laboratorios Del Dr. Esteve, S.A. Uso de los compuestos 2,5-dihidroxibencenosulfonicos para la fabricacion de un medicamento.
DK1590144T3 (en) * 2002-12-10 2015-11-09 Nortec Dev Ass Process for preparing biologically active formulations
WO2004064807A1 (en) * 2003-01-23 2004-08-05 Amorepacific Corporation Sustained-release preparations and method for producing the same
US20070059358A1 (en) * 2003-07-02 2007-03-15 Tianjin Tasly Pharmaceutical Co., Ltd., China Matrix adjuvants and the drop pills prepared with them
TW200526274A (en) 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) * 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
AR048033A1 (es) 2004-03-12 2006-03-22 Smithkline Beecham Plc Composicion farmaceutica para moldear componentes que comprende copolimero de poli(met)acrilato, cubierta, conector o espaciador de capsula moldeado por inyeccion que tiene la composicion farmaceutica y forma de dosificacion farmaceutica de multicomponentes a partir de dicha composicion
SI1765292T1 (en) 2004-06-12 2018-04-30 Collegium Pharmaceutical, Inc. Formulations of medicines to discourage abuse
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
WO2006009403A1 (en) * 2004-07-22 2006-01-26 Amorepacific Corporation Sustained-release preparations containing topiramate and the producing method thereof
ATE497995T1 (de) * 2004-12-27 2011-02-15 Kaneka Corp Thermoplastharzzusammensetzung
JP5185534B2 (ja) * 2004-12-27 2013-04-17 株式会社カネカ 凝固ラテックス粒子の製造方法
US20070270539A1 (en) * 2004-12-27 2007-11-22 Koji Yui Thermoplastic Resin Composition
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US7803413B2 (en) * 2005-10-31 2010-09-28 General Mills Ip Holdings Ii, Llc. Encapsulation of readily oxidizable components
US20070184163A1 (en) * 2006-02-07 2007-08-09 International Flavors, & Fragrances Inc. Non-hygroscopic flavor particles
EP2010158B1 (en) * 2006-04-26 2016-02-17 Alphapharm Pty Ltd. Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
EP2144599B1 (en) * 2007-03-02 2010-08-04 Farnam Companies, Inc. Sustained release pellets comprising wax-like material
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
EP2219624A2 (en) 2007-11-08 2010-08-25 Glaxo Group Limited Pharmaceutical formulations
WO2009088318A1 (ru) * 2007-12-29 2009-07-16 Physics Depertment M.V. Lomonosov Moscow State University Магнитные полимерные гранулы и способы их применения
CA2710986A1 (en) * 2007-12-29 2009-07-16 Physics Department M.V. Lomonosov Moscow State University Magnetic polymer pellets and a method of generating the blocking gel plug
BRPI0906467C1 (pt) 2008-01-25 2021-05-25 Gruenenthal Gmbh forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
KR101094231B1 (ko) * 2008-02-18 2011-12-14 하나제약 주식회사 서방성 고형 제제 및 그의 제조방법
KR101690094B1 (ko) 2008-05-09 2016-12-27 그뤼넨탈 게엠베하 분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법
MX2011000825A (es) * 2008-07-22 2011-02-25 Gen Mills Inc Productos frutales que contienen acidos grasos omega-3.
EP2437616A4 (en) * 2009-06-05 2013-08-21 Gen Mills Inc ENCAPSULATED OMEGA-3 FATTY ACIDS FOR THE MANUFACTURE OF BAKERY PRODUCTS
PE20121067A1 (es) 2009-07-22 2012-09-05 Gruenenthal Chemie Forma de dosificacion de liberacion controlada extruida por fusion en caliente
WO2011009604A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
CA2782556C (en) 2009-12-02 2018-03-27 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
JP2013526523A (ja) 2010-05-11 2013-06-24 シマ ラブス インク. メトプロロールを含むアルコール耐性持続放出性経口剤形
WO2012028319A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
CA2808541C (en) 2010-09-02 2019-01-08 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
DE102011018403A1 (de) * 2011-04-21 2012-10-25 Automatik Plastics Machinery Gmbh Verfahren zur Herstellung von pharmazeutischen Erzeugnissen aus einem Schmelzematerial
AR087360A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
KR20140053158A (ko) 2011-07-29 2014-05-07 그뤼넨탈 게엠베하 즉시 약물 방출을 제공하는 탬퍼-저항성 정제
CA2864949A1 (en) 2012-02-28 2013-09-06 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
JP6282261B2 (ja) 2012-04-18 2018-02-21 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 不正使用防止および過量放出防止医薬剤形
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CA2913209A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
EP3003279A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
RU2535049C1 (ru) * 2013-07-11 2014-12-10 Общество с ограниченной ответственностью "КОМПАНИЯ "ДЕКО" Способ получения стабилизированной субстанции дротаверина гидрохлорида
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
CA2947786A1 (en) 2014-05-12 2015-11-19 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising tapentadol
WO2015181059A1 (en) 2014-05-26 2015-12-03 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
JP2018517676A (ja) 2015-04-24 2018-07-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時放出および溶媒抽出に対する耐性を有する改変防止製剤
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
CN111372578A (zh) 2017-08-24 2020-07-03 阿达玛斯药物有限责任公司 金刚烷胺组合物、其制备和使用方法
EP3965733A4 (en) 2019-05-07 2023-01-11 Clexio Biosciences Ltd. ABUSE DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
CN116098871A (zh) * 2022-12-16 2023-05-12 深圳市瑞华制药技术有限公司 一种美沙拉秦缓释颗粒的制备工艺

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL297357A (ru) 1962-08-31
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
FR2581541B1 (fr) * 1985-05-09 1988-05-20 Rhone Poulenc Sante Nouvelles compositions pharmaceutiques permettant la liberation prolongee d'un principe actif et leur procede de preparation
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
DE3612211A1 (de) 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
US5326572A (en) * 1989-03-23 1994-07-05 Fmc Corporation Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions
US4983399A (en) * 1989-10-18 1991-01-08 Eastman Kodak Company Direct compression carrier composition
WO1993007859A1 (en) * 1991-10-23 1993-04-29 Warner-Lambert Company Novel pharmaceutical pellets and process for their production
DE4138513A1 (de) 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform

Similar Documents

Publication Publication Date Title
RU96122469A (ru) Матричные гранулы продленного действия и способ их получения
BR9507328A (pt) Pelotas de matriz de lenta liberaçãco e processo em um estágio continuo para produzir as mesma
RS50054B (sr) Kompozicije oksikodona sa kontrolisanim oslobađanjem
CA2046679A1 (en) Pharmaceutical composition for rapid suspension in water
SE8405615L (sv) Farmaceutiska tabletter med depaverkan och forfarande for deras framstellning
ATE123649T1 (de) Feste pharmazeutische retardform.
ES535129A0 (es) Un procedimiento para la obtencion de polimeros porosos reticulados para liberacion controlada de farmacos
DE3883251D1 (de) Latex enthaltende agrochemische zusammensetzungen.
KR900700021A (ko) 냉동 분쇄 어육 첨가용 품질 개량제 및 이것을 사용한 냉동 분쇄어육의 제조방법
CA1261271A (en) Solid medicament formulation containing nitrendipine and a process for its preparation
EA199700093A1 (ru) ЛЕКАРСТВЕННЫЕ ФОРМЫ ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕНИЯ, СОДЕРЖАЩИЕ β-ЛАКТАМНЫЙ АНТИБИОТИК
IE870064L (en) Sustained release capsule
EA200100491A1 (ru) Покрытые оболочкой частицы гранулированного кристаллического ибупрофена
PT87404A (pt) Process for the preparation of an additive for the fire extinction water containing high polymers
EP0297866A3 (en) Therapeutic agents
KR840004347A (ko) 불안정한 약물 또는 음식물 첨가물의 안정화
RU2001124607A (ru) Составы на основе бетагистина с контролируемым высвобождением
DK136487A (da) Farmaceutisk praeparat indeholdende ibuprofen og fremgangsmaade til fremstilling deraf
KR890007745A (ko) 약학조성물 및 그의 제조방법
KR900007763A (ko) 서방성 옥사미드 비료 및 그 제조방법
JPS52141852A (en) Synthetic resin composition
JPS6430A (en) Gradually releasing preparation
KR910002358A (ko) 중체량(weight gain)-증가제
YU130890A (sh) Postupak za pravljenje čvrstog farmaceutskog preparata za oslobadjanje aktivne supstance
JPS57189647A (en) Assorted feed for aquatic animal